RFID for Intraoperative Localization of Non-Palpable Breast Lesions: A Single-Center Experience

Introduction: Breast cancer screening has increased the detection of non-palpable lesions, requiring accurate intraoperative localization to ensure oncologic safety and preserve cosmesis. Wire-free methods such as radiofrequency identification (RFID) provide radiation-free, patient-friendly alternatives to traditional wire-guided techniques. Methods: We conducted a retrospective single-center study of patients undergoing breast-conserving surgery with RFID localization between June 2021 and August 2023. Collected data included timing of device placement and surgery, number of devices, device–lesion and device–skin distances, specimen and lesion volumes, margin, and complications of the device and surgery were evaluated. Results: A total of 131 RFID devices were placed for 108 lesions; two devices were required in 22% of cases. Devices were implanted a mean of 3 days before surgery (range 0–42). The mean distance to the lesion was 0.3 mm and to the skin 30 mm. The mean specimen volume was 144 cm³, and mean lesion volume 5 cm³. Malignancy was confirmed in 91% of lesions, with a mean tumor size of 13 mm. Negative margins were achieved in 88% of malignant cases. Twelve patients (12.2%) required re-excision, with residual disease in 67%. All devices were successfully retrieved. No device-related complications occurred; surgical complications were observed in 4% of cases. Conclusion: RFID localization with LOCalizer™ is a safe, effective and radiation-free technique for non palpable breast lesions. It enables accurate excision with high negative margin rates, low re-excision rates, and no device-related morbidity and allows scheduling flexibility.